OS Therapies Incorporated (OSTX) Cash Flow Statement
Where OSTX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$14.24B
- Capital expenditures
- $466,423
- Free cash flow
- −$14.24B
- Returned to shareholders
- —
- Change in cash
- −$5.26B cash at year-end $269.8M
Drawn to scale: where the cash came from and how it was used. Hover for values.
OSTX operating cash flow, capex and free cash flow
OSTX cash flow trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$2.41B2020 | −$14.24B2025 | — | |
| Capital expenditures | $2.0M2020 | $466,4232025 | −25.4%/yr | |
| Free cash flow | −$2.42B2020 | −$14.24B2025 | — | |
| Stock-based compensation | $02023 | $4.27B2025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
OSTX cash flow by activity
OSTX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
OSTX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$28.75B | −$8.9M | −$7.8M | −$6.3M | −$7.4M | −$6.03B |
| Depreciation & amortization | $363,085 | $2,780 | $4,220 | $805 | $805 | $67,000 |
| Stock-based compensation | $4.27B | $268,300 | $0 | — | — | — |
| Change in working capital | $9.1M | −$129,639 | $2.0M | $947,330 | $574,668 | $964.4M |
| Other non-cash items | $10.24B | $1.5M | $2.8M | $1.5M | $2.4M | $2.65B |
| Cash from operating activities | −$14.24B | −$7.3M | −$3.0M | −$3.8M | −$4.4M | −$2.41B |
| Investing activities | ||||||
| Capital expenditures | −$466,423 | $0 | $0 | $0 | −$11,934 | −$2.0M |
| Investments (net) | — | $0 | $1,145 | $230,881 | $200,473 | — |
| Acquisitions & other investing | −$466.0M | — | $0 | $0 | $11,934 | $160.3M |
| Cash from investing activities | −$466.4M | — | $1,145 | $230,881 | $200,473 | $158.3M |
| Financing activities | ||||||
| Dividends paid | — | −$31.2M | — | — | — | — |
| Share repurchases & issuance (net) | $6.40B | — | — | — | — | — |
| Net borrowing (repayment) | $0 | $1.5M | $3.2M | $3.8M | $3.0M | — |
| Shares issued | $8.9M | $11.3M | $0 | $0 | $0 | $0 |
| Other financing | $3.03B | $31.2M | −$284,176 | −$172,021 | $100,000 | $3.48B |
| Cash from financing activities | $9.44B | $12.8M | $2.9M | $3.7M | $3.1M | $3.48B |
| Summary | ||||||
| Net change in cash | −$5.26B | $5.5M | −$132,498 | $90,692 | −$1.2M | $1.23B |
| Cash at end of period | $269.8M | $5.5M | $38,982 | $171,480 | $80,788 | $1.23B |
| Free cash flow | −$14.24B | −$7.3M | −$3.0M | −$3.8M | −$4.4M | −$2.42B |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$8.6M | −$10.4M | −$28.74B | −$6.9M | −$4.5M | −$3.9M | −$3.0M | −$2.88B | −$1.6M | −$1.5M | −$1.5M | −$2.0M |
| Depreciation & amortization | $124,938 | $124,938 | $124,938 | $124,938 | $112,514 | $695 | $1,390 | $338,289 | $695 | $695 | $213,235 | $3,315 |
| Stock-based compensation | $1.3M | $1.4M | $4.26B | $814,932 | $905,182 | $941,283 | — | $0 | $0 | $0 | — | — |
| Change in working capital | $1.6M | $3.9M | $6.9M | $1.0M | $1.5M | −$299,265 | $313,444 | −$563.9M | $229,067 | $237,832 | $380,173 | $113,963 |
| Other non-cash items | $47,109 | $358,172 | $24.46B | $197,401 | −$292,042 | −$207,738 | $301,823 | $54.0M | $446,527 | $578,736 | $0 | $981,143 |
| Cash from operating activities | −$5.5M | −$4.6M | −$3.7M | −$4.7M | −$2.4M | −$3.4M | −$2.4M | −$3.38B | −$881,191 | −$641,729 | −$871,160 | −$876,569 |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | −$466,423 | −$466,423 | −$316,423 | −$150,000 | −$3 | $0 | $0 | $0 | −$19 | $0 |
| Investments (net) | — | — | — | $0 | −$292,787 | −$173,636 | $0 | $0 | $0 | $0 | $19 | $0 |
| Acquisitions & other investing | — | — | −$465.5M | −$465.5M | $316,423 | $150,000 | — | — | — | — | $19 | — |
| Cash from investing activities | — | — | −$466.0M | −$466.0M | −$292,787 | −$173,636 | — | — | — | — | $19 | — |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | $6.40B | $6.40B | — | — | — | — | — | — | — | — |
| Net borrowing (repayment) | $0 | $1.8M | $0 | $0 | $0 | $0 | $0 | −$250,000 | — | — | — | — |
| Shares issued | $4.8M | $0 | $7.9M | $0 | $2.5M | $1.1M | $6.0M | $5.2M | $0 | $0 | $0 | $0 |
| Other financing | $0 | $3.4M | −$6.40B | −$6.39B | $0 | $0 | $0 | $5.14B | $875,885 | $702,978 | $894,064 | $843,406 |
| Cash from financing activities | $4.8M | $5.2M | $2.1M | $3.8M | $2.5M | $1.1M | $6.0M | $5.15B | $875,885 | $702,978 | $894,064 | $843,406 |
| Summary | ||||||||||||
| Net change in cash | −$712,517 | $648,000 | −$1.6M | −$925,387 | −$168,994 | −$2.6M | $3.7M | $1.76B | −$5,306 | $61,249 | $22,923 | −$33,163 |
| Cash at end of period | $205,035 | $917,552 | $269,830 | $1.9M | $2.8M | $3.0M | $5.5M | $1.86B | $94,925 | $100,231 | $38,982 | $16,059 |
| Free cash flow | −$5.5M | −$4.6M | −$3.7M | −$4.7M | −$2.7M | −$3.6M | −$2.4M | −$3.38B | −$881,191 | −$641,729 | −$871,141 | −$876,569 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
OSTX cash generation
In fiscal 2025 (ended December 31, 2025), OS Therapies generated -$14.2 billion of cash from operations and spent $0.5 million on capital expenditures, leaving free cash flow of -$14.2 billion. Cash and equivalents fell by $5.3 billion over the year.
Related: OSTX income statement, OSTX balance sheet. See the OSTX stock overview for the latest quote and news.
OSTX cash flow FAQ
What is OS Therapies's free cash flow?
OS Therapies's free cash flow was -$14.2 billion in fiscal 2025: -$14.2 billion of operating cash flow minus $0.5 million of capital expenditures It was -$7.3 million a year earlier..
How much cash does OS Therapies generate from operations?
OS Therapies generated -$14.2 billion of cash from operating activities in fiscal 2025.
How much does OS Therapies spend on capital expenditures?
OS Therapies spent $0.5 million on capital expenditures in fiscal 2025.